Showing 1671-1680 of 1735 results for "".
- Data Published on Acthar Gel Disease Status and Utilization Patterns in Uveitis Patientshttps://modernod.com/news/data-published-on-acthar-gel-disease-status-and-utilization-patterns-in-uveitis-patients/2476455/Mallinckrodt announced data from a retrospective chart review that analyzed physician assessments of 91 U.S. patients diagnosed with uveitis who had been treated with Acthar Gel (repository corticotropin injection) in the previous 12 months. All patients had completed
- Oxurion NV Announces Full Enrollment of Its Phase 2 Trial Evaluating Combination of Anti-PlGF (THR-317) and Anti-VEGF (Ranibizumab) for the Treatment of DMEhttps://modernod.com/news/oxurion-nv-announces-full-enrollment-of-its-phase-2-trial-evaluating-combination-of-anti-plgf-thr-317-and-anti-vegf-ranibizumab-for-the-treatment-of-dme/2476439/Oxurion NV announced that all patients have been enrolled in its phase 2 trial evaluating its THR-317, a humanized antibody against placental growth factor (PlGF), in combination with anti-VEGF (ranibizumab), an anti-vascular endothelial growth factor (VEGF) antibody, for the treatment of diabeti
- Compulink Previews New User Interface for its Optometry SMART EHR at Vision Expo Easthttps://modernod.com/news/compulink-previews-new-user-interface-for-its-optometry-smart-ehr-at-vision-expo-east/2476404/Compulink Healthcare Solutions, the creator of Advantage SMART Practice, an all-in-one EHR and practice management solution powered by artificial intelligence (AI), previewed the new user interface for its Eyecare Advantage at Vision Expo this week. Designed by a team of usability experts,
- BioTime Announces Closing of Acquisition of Asterias Biotherapeuticshttps://modernod.com/news/biotime-announces-closing-of-acquisition-of-asterias-biotherapeutics/2476362/BioTime announced the closing of its previously reported acquisition of Asterias Biotherapeutics, whereby BioTime has acquired through a merger, all of the remaining outstanding common stock of Asterias which was not previously owned by BioTime. As a result of the acquisition, Asterias became a w
- New Laser Helps Doctors Image Full Eye in 3Dhttps://modernod.com/news/new-laser-helps-doctors-image-full-eye-in-3d/2476348/Scientists have developed a laser-based technique that can produce a full 3D image of all the layers of the retina, allowing doctors to better diagnose and treat eye diseases such as cataracts, diabetic retinopathy, and cancer, according to an Octlight news release. Researchers from the Te
- Roche Acquires Spark Therapeutics in $4.8 Billion Dealhttps://modernod.com/news/roche-acquires-spark-therapeutics-in-4-3-billion-deal/2476268/Swiss pharma giant Roche acquired and Philadelphia-based gene therapy company Spark Therapeutics in an all cash transaction worth $4.8 billion, or $114.50 per share. The merger has been unanimously approved by the boards of Spark Therap
- EyeBrain Medical and IDOC Announce Partnership to Bring Neurolens to IDOC Independent Optometristshttps://modernod.com/news/eyebrain-medical-and-idoc-announce-partnership-to-bring-neurolens-to-idoc-independent-optometrists/2476270/IDOC and eyeBrain Medical announced a multiyear partnership to bring neurolens prescription lenses to all IDOC members across the United States. Neurolenses are the first and only prescription lenses that add a contoured prism to bring the eyes into alignment. Contoured prisms have been shown in
- ReNeuron Group Announces Positive Preliminary Data in US Retinitis Pigmentosa Trialhttps://modernod.com/news/reneuron-group-announces-positive-preliminary-data-in-us-retinitis-pigmentosa-trial/2476276/ReNeuron Group announced positive preliminary results in the company’s ongoing phase 1/2 clinical trial of its human retinal progenitor cells (hRPC) cell therapy candidate in retinitis pigmentosa (RP). All three subjects in the first cohort of the phase 2 part of the trial have demonstrate
- Bausch Health to Purchase Majority of Synergy Pharmaceuticals’ Assets, Including Trulancehttps://modernod.com/news/bausch-health-to-purchase-majority-of-synergy-pharmaceuticals-assets-including-trulance/2479614/Bausch Health announced a deal to purchase nearly all of the assets of bankrupt drugmaker Synergy Pharmaceuticals for about $200 million in cash, with the transaction including the constipation treatment Trulance (plecanatide), according to FirstWord. Bausch Health CEO Joseph Papa noted that the
- Criminal Case Against James Mazzo Dismissedhttps://modernod.com/news/criminal-case-against-james-mazzo-dismissed/2476151/After a legal battle that spanned a decade, the insider trading criminal case against ophthalmic executive James Mazzo has come to an end. Late Thursday at the Ronald Reagan Federal Building in Santa Ana, California, federal prosecutors asked Judge Andrew Guilford to dismiss all criminal c